Morphine Tolerance and Physical Dependence Are Altered in Conditional HIV-1 Tat Transgenic Mice
- 1 January 2016
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 356 (1) , 96-105
Abstract
Despite considerable evidence that chronic opiate use selectively affects the pathophysiologic consequences of human immunodeficiency virus type 1 (HIV-1) infection in the nervous system, few studies have examined whether neuro-acquired immune deficiency syndrome (neuroAIDS) might intrinsically alter the pharmacologic responses to chronic opiate exposure. This is an important matter because HIV-1 and opiate abuse are interrelated epidemics, and HIV-1 patients are often prescribed opiates as a treatment of HIV-1–related neuropathic pain. Tolerance and physical dependence are inevitable consequences of frequent and repeated administration of morphine. In the present study, mice expressing HIV-1 Tat in a doxycycline (DOX)–inducible manner [Tat(+)], their Tat(−) controls, and control C57BL/6 mice were chronically exposed to placebo or 75-mg morphine pellets to explore the effects of Tat induction on morphine tolerance and dependence. Antinociceptive tolerance and locomotor activity tolerance were assessed using tail-flick and locomotor activity assays, respectively, and physical dependence was measured with the platform-jumping assay and recording of other withdrawal signs. We found that Tat(+) mice treated with DOX [Tat(+)/DOX] developed an increased tolerance in the tail-flick assay compared with control Tat(−)/DOX and/or C57/DOX mice. Equivalent tolerance was developed in all mice when assessed by locomotor activity. Further, Tat(+)/DOX mice expressed reduced levels of physical dependence to chronic morphine exposure after a 1-mg/kg naloxone challenge compared with control Tat(−)/DOX and/or C57/DOX mice. Assuming the results seen in Tat transgenic mice can be generalized to neuroAIDS, our findings suggest that HIV-1-infected individuals may display heightened analgesic tolerance to similar doses of opiates compared with uninfected individuals and show fewer symptoms of physical dependence.Keywords
This publication has 66 references indexed in Scilit:
- Morphine potentiates neurodegenerative effects of HIV-1 Tat through actions at -opioid receptor-expressing gliaBrain, 2011
- Activation of Cannabinoid Type 2 Receptors Inhibits HIV-1 Envelope Glycoprotein gp120-Induced Synapse LossMolecular Pharmacology, 2011
- Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: Comparison of different mouse strainsBrain, Behavior, and Immunity, 2011
- Interactive Comorbidity between Opioid Drug Abuse and HIV-1 TatThe American Journal of Pathology, 2010
- Extended-release morphine sulfate in treatment of severe acute and chronic painJournal of Pain Research, 2010
- Regional Heterogeneity and Diversity in Cytokine and Chemokine Production by Astroglia: Differential Responses to HIV-1 Tat, gp120, and Morphine Revealed by Multiplex AnalysisJournal of Proteome Research, 2010
- Morphine Tolerance in the Mouse Ileum and ColonThe Journal of Pharmacology and Experimental Therapeutics, 2008
- CCL5/RANTES Gene Deletion Attenuates Opioid-Induced Increases in Glial CCL2/MCP-1 Immunoreactivity and Activation in HIV-1 Tat-Exposed MiceJournal of Neuroimmune Pharmacology, 2008
- Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV‐1 tat transgenic miceGlia, 2008
- Induction of autophagy in neurite degeneration of mouse superior cervical ganglion neuronsEuropean Journal of Neuroscience, 2007